
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DUSP22 CRISPR/Cas9 KO Plasmid (m) | sc-430587 | 20 µg | $397.00 |
Dusp22 encodes dual specificity phosphatase 22 (DUSP22), an atypical MAPK phosphatase that modulates phosphorylation-dependent signaling by dephosphorylating serine/threonine and tyrosine residues on select substrates. In mouse immune and non-immune cells, DUSP22 has been linked to regulation of MAPK pathway dynamics, including stress- and mitogen-responsive signaling nodes that shape transcriptional outputs such as cytokine programs, activation thresholds, and apoptosis. Through its impact on kinase–phosphatase balance, DUSP22 influences cell proliferation and differentiation decisions that are frequently perturbed in inflammatory conditions and cancer biology. Altered DUSP22 signaling has been associated with immune dysregulation and oncogenic pathway rewiring, making it relevant for mechanistic studies of signaling-dependent phenotypes.
DUSP22 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Dusp22 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Dusp22 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Dusp22 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DUSP22 protein expression.
This CRISPR knockout system enables efficient generation of Dusp22-deficient cell models for investigation of DUSP22 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.